Reindl M - Search Results

1

International multicenter examination of MOG antibody assays.

Reindl M, Schanda K, Woodhall M, Tea F, Ramanathan S, Sagen J, Fryer JP, Mills J, Teegen B, Mindorf S, Ritter N, Krummrei U, Stöcker W, Eggert J, Flanagan EP, Ramberger M, Hegen H, Rostasy K, Berger T, Leite MI, Palace J, Irani SR, Dale RC, Probst C, Probst M, Brilot F, Pittock SJ, Waters P. Reindl M, et al. Neurol Neuroimmunol Neuroinflamm. 2020 Feb 5;7(2):e674. doi: 10.1212/NXI.0000000000000674. Print 2020 Mar 5. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32024795 Free PMC article.

2

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.

Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Deisenhammer F, et al. Among authors: reindl m. Neurology. 1999 Apr 12;52(6):1239-43. doi: 10.1212/wnl.52.6.1239. Neurology. 1999. PMID: 10214750

3

Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.

Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, Poewe W, Berger T. Reindl M, et al. Brain. 1999 Nov;122 ( Pt 11):2047-56. doi: 10.1093/brain/122.11.2047. Brain. 1999. PMID: 10545390 Clinical Trial.

4

A critical comparison of frequently used methods for the analysis of tumor necrosis factor-alpha expression by human immune cells.

Mayringer I, Reindl M, Berger T. Mayringer I, et al. Among authors: reindl m. J Immunol Methods. 2000 Feb 21;235(1-2):33-40. doi: 10.1016/s0022-1759(99)00208-2. J Immunol Methods. 2000. PMID: 10675755

5

Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis.

Berger T, Reindl M. Berger T, et al. Among authors: reindl m. J Neural Transm Suppl. 2000;(60):351-60. doi: 10.1007/978-3-7091-6301-6_25. J Neural Transm Suppl. 2000. PMID: 11205153 Review.

6

The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls.

Haase CG, Guggenmos J, Brehm U, Andersson M, Olsson T, Reindl M, Schneidewind JM, Zettl UK, Heidenreich F, Berger T, Wekerle H, Hohlfeld R, Linington C. Haase CG, et al. Among authors: reindl m. J Neuroimmunol. 2001 Mar 1;114(1-2):220-5. doi: 10.1016/s0165-5728(00)00462-8. J Neuroimmunol. 2001. PMID: 11240035

7

Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b.

Deisenhammer F, Reindl M, Berger T. Deisenhammer F, et al. Among authors: reindl m. J Interferon Cytokine Res. 2001 Mar;21(3):167-71. doi: 10.1089/107999001750133195. J Interferon Cytokine Res. 2001. PMID: 11331039

8

Increased intrathecal production of apolipoprotein D in multiple sclerosis.

Reindl M, Knipping G, Wicher I, Dilitz E, Egg R, Deisenhammer F, Berger T. Reindl M, et al. J Neuroimmunol. 2001 Oct 1;119(2):327-32. doi: 10.1016/s0165-5728(01)00378-2. J Neuroimmunol. 2001. PMID: 11585636

9

Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis.

Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. Egg R, et al. Among authors: reindl m. Mult Scler. 2001 Oct;7(5):285-9. doi: 10.1177/135245850100700503. Mult Scler. 2001. PMID: 11724443

10

Antibody response to myelin oligodendrocyte glycoprotein and myelin basic protein depend on familial background and are partially associated with human leukocyte antigen alleles in multiplex families and sporadic multiple sclerosis.

Lutterotti A, Reindl M, Gassner C, Poustka K, Schanda K, Deisenhammer F, Berger T. Lutterotti A, et al. Among authors: reindl m. J Neuroimmunol. 2002 Oct;131(1-2):201-7. doi: 10.1016/s0165-5728(02)00271-0. J Neuroimmunol. 2002. PMID: 12458053

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

410 results

Search Page